Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors

Evidence-Based Medicine

Volumn 16, Issue 1, 2011, Pages 7-8

  Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLICLAZIDE; METFORMIN; NATEGLINIDE; ROSIGLITAZONE; TOLBUTAMIDE;

ADULT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CELL PROTECTION; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; NOTE; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 79551492620     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1100     Document Type: Note

References (8)

1. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7. (Pubitemid 34680970)
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
3. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
4. Karunakaran S, Hammersley MS, Morris RJ, et al. The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metab Clin Exp 1997;46(12 Suppl 1):56-60.
5. Sartor G, Scherstén B, Carlström S, et al. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-9. (Pubitemid 10157188)
6. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010;9:12.
7. Derosa G, Maffioli P, Ferrari I, et al. Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients. Horm Metab Res 2010; doi: 10.1055/s-0030-1255036.
8. Derosa G, Maffioli P, Salvadeo SAT, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetic patients. Metabolism 2010;59:887-95.